Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The mechanisms and strategies for Alzheimer's disease prevention: An update.

Acta pharmaceutica Sinica. B·2026

Same author

<i>Saussurea involucrata</i> Cultures for High-Altitude Illness: Enhancing Hypoxia Tolerance and Protecting Against Acute/Chronic Hypoxic Injury.

Nutrients·2026

Same author

ZIF-8 Hydrogel-Mediated Regulation of Macrophage Phenotype Accelerates Frostbite Wound Healing.

Biomedicines·2026

Same author

Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives.

Acta pharmaceutica Sinica. B·2026

Same author

Endogenic transferrin-targeted cell membrane-coated biomimetic lipo-complexes for efficient targeting and enhanced antitumor efficacy in orthotopic glioblastoma.

Acta pharmaceutica Sinica. B·2026

Same author

A multifunctional injectable nanocomposite hydrogel for precision keloid therapy via ECM remodeling and local pruritus relief.

Journal of nanobiotechnology·2026

Search research articles

Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Recent progress in tumor pH targeting nanotechnology.

Eun Seong Lee¹, Zhonggao Gao, You Han Bae

¹Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, 421 Wakara Way, Suite 315, Utah 84108, USA.

Journal of Controlled Release : Official Journal of the Controlled Release Society

|June 24, 2008

Summary

This summary is machine-generated.

pH-sensitive nanocarriers target acidic solid tumors, overcoming multidrug resistance. This nanotechnology offers a general strategy for cancer treatment by exploiting the tumor microenvironment.

More Related Videos

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

Related Experiment Videos

Last Updated: Jan 2, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

Area of Science:

Biomedical Engineering
Nanotechnology
Oncology

Background:

Solid tumors often exhibit a slightly acidic extracellular pH, creating a unique microenvironment.
Conventional tumor targeting methods face limitations due to tumor heterogeneity.
The acidic tumor microclimate is a common characteristic across many solid tumors.

Purpose of the Study:

To review advancements in pH-sensitive nanotechnology for cancer therapy.
To highlight the development of pH-sensitive polymeric micelles and nanogels.
To discuss the potential of these nanocarriers in overcoming multidrug resistance.

Main Methods:

Development of pH-sensitive polymeric micelles and nanogels.
Utilizing endosomal/lysosomal acidity for triggered drug release.
Incorporating endosomolytic capabilities into nanocarriers.
Evaluating the efficacy of nanocarriers in overcoming multidrug resistance in tumors.

Main Results:

pH-sensitive nanocarriers effectively target the acidic extracellular pH of solid tumors.
Combined triggered release and endosomolytic features enhance drug delivery.
Nanocarriers demonstrate success in overcoming multidrug resistance in various tumor models.
pH targeting offers a more generalizable strategy compared to cell surface targeting.

Conclusions:

pH-sensitive nanotechnology presents a promising approach for solid tumor treatment.
Exploiting the acidic tumor microenvironment is a versatile strategy.
Further development of these nanocarriers could significantly impact cancer therapy and drug resistance management.